Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells

Cancer Research

Volumn 68, Issue 21, 2008, Pages 8918-8927

  Taniguchi, Hiroya ^a,b   Yoshida, Tatsushi ^a   Horinaka, Mano ^a   Yasuda, Takashi ^a,b   Goda, Ahmed E ^a,c   Konishi, Masako ^a   Wakada, Miki ^a   Kataoka, Keisho ^b   Yoshikawa, Toshikazu ^b   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Tanta University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALEIN; CCAAT ENHANCER BINDING PROTEIN; DEATH RECEPTOR 5; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SCAVENGER; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; BINDING SITE; BLOOD CELL; CANCER CELL; CANCER RESISTANCE; CELL SPECIFICITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; LIVER CELL; MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SENSITIZATION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOWN-REGULATION; FLAVANONES; HUMANS; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, MESSENGER; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP;

EID: 55349089182     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1120     Document Type: Article

References (44)

1. Sekiya K, Okuda H. Selective inhibition of platelet lipoxygenase by baicalein. Biochem Biophys Res Commun 1982;105:1090-5.
2. Wong BC, Wang WP, Cho CH, et al. 12-lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis 2001;22:1349-54.
3. Tong WG, Ding XZ, Witt RC, et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002;1:929-35.
4. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 2002;62:2721-7.
5. Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1999;1472:643-50.
6. Wang J, Yu Y, Hashimoto F, Sakata Y, Fujii M, Hou DX. Baicalein induces apoptosis through ROS-mediated mitochondrial dysfunction pathway in HL-60 cells. Int J Mol Med 2004;14:627-32.
7. Ozben T. Oxdative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007;96:2181-96.
8. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004;7:97-110.
9. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosisinducing ligand in vivo. Nat Med 1999;5:157-63.
10. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
11. Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006;12:2640-6.
12. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001;3:535-46.
13. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;2:161-9.
14. Zerafa N, Westwood JA, Cretney E, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 2005;175:5586-90.
15. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
16. Pan G, Ni J, Wei YF, Yu GL, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
17. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60.
18. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003;200:327-35.
19. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-40.
20. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37.
21. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001;507:381-5.
22. 2 induces apoptosis through activation of the CHOP gene in HeLa cells. Biochem Biophys Res Commun 2003;311:17-23.
23. Horinaka M, Yoshida T, Shiraishi T, et al. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005;24:7180-9.
24. Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 2004;279:45495-502.
25. Hanasaki Y, Ogawa S, Fukui S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic Biol Med 1994;16:845-50.
26. Miura YH, Tomita Y, Watanabe T, Hirayama T, Fukui S. Active oxygens generation by flavonoids. Biol Pharm Bull 1998;21:93-6.
27. Woo AY, Cheng CH, Waye MM. Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res 2005;65:244-53.
28. Leung HWC, Yang WH, Lai MY, Lin CJ, Lee HZ. Inhibition of 12-lipoxygenase during baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis. Food Chem Toxicol 2007;45:403-11.
29. Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of TRAIL agonists in diseased human liver. Hepatology 2007;46:1498-508.
30. Koschny R, Ganten TM, Sykora J, et al. TRAIL/ Bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007;45:649-58.
31. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
32. Takimoto R, EI-Deiry WS. Wild type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735-43.
33. Hagmann W. 12-Lipoxygenase in human tumor cells. Pathol Oncol Res 1997;3:83-8.
34. Tong WG, Ding XZ, Adrian TE. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2002;296:942-8.
35. Nie D, Nemeth J, Qiao Y, et al. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 2003;20:657-63.
36. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002;365:561-75.
37. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004;11:381-9.
38. Shiraishi T, Yoshida T, Nakata S, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 2005;65:6364-70.
39. Guyton KZ, Xu Q, Holbrook NJ. Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element. Biochem J 1996;314:547-54.
40. Lai WL, Wong NS. ROS mediates 4HPR-induced posttranscriptional expression of the gadd153 gene. Free Radic Biol Med 2005;38:1585-93.
41. Drosopoulos KG, Roberts ML, Cermak L, et al. Transformation by oncogenic ras sensitizes human colon cancer cells to TRAIL-induced apoptosis by upregulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005;280:22856-67.
42. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of myc by activation of the DR5 death receptor pathway. Cancer Cell 2004;5:501-12.
43. Grosse-Wilde A, Voloshanenko O, Bailey SL, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-10.
44. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008;118:111-23.